This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts Offer Insights on Healthcare Companies: Summit Therapeutics (SMMT), BioMarin Pharmaceutical (BMRN) and Thermo Fisher (TMO)

Tipranks - Tipranks - Fri May 22, 9:16AM CDT

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Summit Therapeutics (SMMT), BioMarin Pharmaceutical (BMRN) and Thermo Fisher (TMO).

Meet Samuel – Your Personal Investing Prophet

Summit Therapeutics (SMMT)

Jefferies analyst Faisal Khurshid maintained a Hold rating on Summit Therapeutics today and set a price target of $17.00. The company’s shares closed last Thursday at $17.76.

According to TipRanks.com, Khurshid is a top 100 analyst with an average return of 67.5% and a 61.9% success rate. Khurshid covers the Healthcare sector, focusing on stocks such as 4D Molecular Therapeutics, Abivax SA Sponsored ADR, and Syndax Pharmaceuticals. ;'>

Summit Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $30.83, representing a 72.6% upside. In a report issued on May 8, TipRanks – OpenAI also reiterated a Hold rating on the stock with a $18.00 price target.

See Insiders’ Hot Stocks on TipRanks >>

BioMarin Pharmaceutical (BMRN)

In a report released today, Akash Tewari from Jefferies maintained a Buy rating on BioMarin Pharmaceutical, with a price target of $104.00. The company’s shares closed last Thursday at $52.60.

According to TipRanks.com, Tewari is a 5-star analyst with an average return of 13.4% and a 54.8% success rate. Tewari covers the Healthcare sector, focusing on stocks such as Vertex Pharmaceuticals, Ionis Pharmaceuticals, and Spyre Therapeutics. ;'>

BioMarin Pharmaceutical has an analyst consensus of Moderate Buy, with a price target consensus of $87.53, which is a 67.6% upside from current levels. In a report issued on May 15, J.P. Morgan also initiated coverage with a Buy rating on the stock with a $75.00 price target.

Thermo Fisher (TMO)

In a report released today, Daniel Arias from Stifel Nicolaus maintained a Buy rating on Thermo Fisher, with a price target of $600.00. The company’s shares closed last Thursday at $446.94.

According to TipRanks.com, Arias is a 2-star analyst with an average return of -0.1% and a 42.4% success rate. Arias covers the Healthcare sector, focusing on stocks such as Maravai Lifesciences Holdings, BillionToOne, Inc. Class A, and Tempus AI, Inc. Class A. ;'>

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Thermo Fisher with a $608.93 average price target, representing a 35.0% upside. In a report issued on May 8, Wells Fargo also maintained a Buy rating on the stock with a $615.00 price target.

Read More on SMMT:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).